Candida parapsilosis: from Genes to the Bedside

Renáta Tóth, Jozef Nosek, Héctor M. Mora-Montes, Toni Gabaldon, Joseph M. Bliss, Joshua D. Nosanchuk, Siobhán A. Turner, Geraldine Butler, Csaba Vágvölgyi, Attila Gácser

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

SUMMARYPatients with suppressed immunity are at the highest risk for hospital-acquired infections. Among these, invasive candidiasis is the most prevalent systemic fungal nosocomial infection. Over recent decades, the combined prevalence of non-albicans Candida species outranked Candida albicans infections in several geographical regions worldwide, highlighting the need to understand their pathobiology in order to develop effective treatment and to prevent future outbreaks. Candida parapsilosis is the second or third most frequently isolated Candida species from patients. Besides being highly prevalent, its biology differs markedly from that of C. albicans, which may be associated with C. parapsilosis' increased incidence. Differences in virulence, regulatory and antifungal drug resistance mechanisms, and the patient groups at risk indicate that conclusions drawn from C. albicans pathobiology cannot be simply extrapolated to C. parapsilosis Such species-specific characteristics may also influence their recognition and elimination by the host and the efficacy of antifungal drugs. Due to the availability of high-throughput, state-of-the-art experimental tools and molecular genetic methods adapted to C. parapsilosis, genome and transcriptome studies are now available that greatly contribute to our understanding of what makes this species a threat. In this review, we summarize 10 years of findings on C. parapsilosis pathogenesis, including the species' genetic properties, transcriptome studies, host responses, and molecular mechanisms of virulence. Antifungal susceptibility studies and clinician perspectives are discussed. We also present regional incidence reports in order to provide an updated worldwide epidemiology summary.

Original languageEnglish (US)
JournalClinical microbiology reviews
Volume32
Issue number2
DOIs
StatePublished - Mar 20 2019

Fingerprint

Candida albicans
Candida
Cross Infection
Transcriptome
Virulence
Fungal Drug Resistance
Invasive Candidiasis
Genes
Mycoses
Incidence
Disease Outbreaks
Molecular Biology
Immunity
Epidemiology
Genome
Infection
Pharmaceutical Preparations
Therapeutics

Keywords

  • antifungal
  • Candida parapsilosis
  • epidemiology
  • experimental tools
  • genome
  • host response
  • pathogenicity
  • treatment
  • virulence

ASJC Scopus subject areas

  • Epidemiology
  • Immunology and Microbiology(all)
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Tóth, R., Nosek, J., Mora-Montes, H. M., Gabaldon, T., Bliss, J. M., Nosanchuk, J. D., ... Gácser, A. (2019). Candida parapsilosis: from Genes to the Bedside. Clinical microbiology reviews, 32(2). https://doi.org/10.1128/CMR.00111-18

Candida parapsilosis : from Genes to the Bedside. / Tóth, Renáta; Nosek, Jozef; Mora-Montes, Héctor M.; Gabaldon, Toni; Bliss, Joseph M.; Nosanchuk, Joshua D.; Turner, Siobhán A.; Butler, Geraldine; Vágvölgyi, Csaba; Gácser, Attila.

In: Clinical microbiology reviews, Vol. 32, No. 2, 20.03.2019.

Research output: Contribution to journalReview article

Tóth, R, Nosek, J, Mora-Montes, HM, Gabaldon, T, Bliss, JM, Nosanchuk, JD, Turner, SA, Butler, G, Vágvölgyi, C & Gácser, A 2019, 'Candida parapsilosis: from Genes to the Bedside', Clinical microbiology reviews, vol. 32, no. 2. https://doi.org/10.1128/CMR.00111-18
Tóth R, Nosek J, Mora-Montes HM, Gabaldon T, Bliss JM, Nosanchuk JD et al. Candida parapsilosis: from Genes to the Bedside. Clinical microbiology reviews. 2019 Mar 20;32(2). https://doi.org/10.1128/CMR.00111-18
Tóth, Renáta ; Nosek, Jozef ; Mora-Montes, Héctor M. ; Gabaldon, Toni ; Bliss, Joseph M. ; Nosanchuk, Joshua D. ; Turner, Siobhán A. ; Butler, Geraldine ; Vágvölgyi, Csaba ; Gácser, Attila. / Candida parapsilosis : from Genes to the Bedside. In: Clinical microbiology reviews. 2019 ; Vol. 32, No. 2.
@article{8549dab85f9a4efeae57a84c905c5234,
title = "Candida parapsilosis: from Genes to the Bedside",
abstract = "SUMMARYPatients with suppressed immunity are at the highest risk for hospital-acquired infections. Among these, invasive candidiasis is the most prevalent systemic fungal nosocomial infection. Over recent decades, the combined prevalence of non-albicans Candida species outranked Candida albicans infections in several geographical regions worldwide, highlighting the need to understand their pathobiology in order to develop effective treatment and to prevent future outbreaks. Candida parapsilosis is the second or third most frequently isolated Candida species from patients. Besides being highly prevalent, its biology differs markedly from that of C. albicans, which may be associated with C. parapsilosis' increased incidence. Differences in virulence, regulatory and antifungal drug resistance mechanisms, and the patient groups at risk indicate that conclusions drawn from C. albicans pathobiology cannot be simply extrapolated to C. parapsilosis Such species-specific characteristics may also influence their recognition and elimination by the host and the efficacy of antifungal drugs. Due to the availability of high-throughput, state-of-the-art experimental tools and molecular genetic methods adapted to C. parapsilosis, genome and transcriptome studies are now available that greatly contribute to our understanding of what makes this species a threat. In this review, we summarize 10 years of findings on C. parapsilosis pathogenesis, including the species' genetic properties, transcriptome studies, host responses, and molecular mechanisms of virulence. Antifungal susceptibility studies and clinician perspectives are discussed. We also present regional incidence reports in order to provide an updated worldwide epidemiology summary.",
keywords = "antifungal, Candida parapsilosis, epidemiology, experimental tools, genome, host response, pathogenicity, treatment, virulence",
author = "Ren{\'a}ta T{\'o}th and Jozef Nosek and Mora-Montes, {H{\'e}ctor M.} and Toni Gabaldon and Bliss, {Joseph M.} and Nosanchuk, {Joshua D.} and Turner, {Siobh{\'a}n A.} and Geraldine Butler and Csaba V{\'a}gv{\"o}lgyi and Attila G{\'a}cser",
year = "2019",
month = "3",
day = "20",
doi = "10.1128/CMR.00111-18",
language = "English (US)",
volume = "32",
journal = "Clinical Microbiology Reviews",
issn = "0893-8512",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Candida parapsilosis

T2 - from Genes to the Bedside

AU - Tóth, Renáta

AU - Nosek, Jozef

AU - Mora-Montes, Héctor M.

AU - Gabaldon, Toni

AU - Bliss, Joseph M.

AU - Nosanchuk, Joshua D.

AU - Turner, Siobhán A.

AU - Butler, Geraldine

AU - Vágvölgyi, Csaba

AU - Gácser, Attila

PY - 2019/3/20

Y1 - 2019/3/20

N2 - SUMMARYPatients with suppressed immunity are at the highest risk for hospital-acquired infections. Among these, invasive candidiasis is the most prevalent systemic fungal nosocomial infection. Over recent decades, the combined prevalence of non-albicans Candida species outranked Candida albicans infections in several geographical regions worldwide, highlighting the need to understand their pathobiology in order to develop effective treatment and to prevent future outbreaks. Candida parapsilosis is the second or third most frequently isolated Candida species from patients. Besides being highly prevalent, its biology differs markedly from that of C. albicans, which may be associated with C. parapsilosis' increased incidence. Differences in virulence, regulatory and antifungal drug resistance mechanisms, and the patient groups at risk indicate that conclusions drawn from C. albicans pathobiology cannot be simply extrapolated to C. parapsilosis Such species-specific characteristics may also influence their recognition and elimination by the host and the efficacy of antifungal drugs. Due to the availability of high-throughput, state-of-the-art experimental tools and molecular genetic methods adapted to C. parapsilosis, genome and transcriptome studies are now available that greatly contribute to our understanding of what makes this species a threat. In this review, we summarize 10 years of findings on C. parapsilosis pathogenesis, including the species' genetic properties, transcriptome studies, host responses, and molecular mechanisms of virulence. Antifungal susceptibility studies and clinician perspectives are discussed. We also present regional incidence reports in order to provide an updated worldwide epidemiology summary.

AB - SUMMARYPatients with suppressed immunity are at the highest risk for hospital-acquired infections. Among these, invasive candidiasis is the most prevalent systemic fungal nosocomial infection. Over recent decades, the combined prevalence of non-albicans Candida species outranked Candida albicans infections in several geographical regions worldwide, highlighting the need to understand their pathobiology in order to develop effective treatment and to prevent future outbreaks. Candida parapsilosis is the second or third most frequently isolated Candida species from patients. Besides being highly prevalent, its biology differs markedly from that of C. albicans, which may be associated with C. parapsilosis' increased incidence. Differences in virulence, regulatory and antifungal drug resistance mechanisms, and the patient groups at risk indicate that conclusions drawn from C. albicans pathobiology cannot be simply extrapolated to C. parapsilosis Such species-specific characteristics may also influence their recognition and elimination by the host and the efficacy of antifungal drugs. Due to the availability of high-throughput, state-of-the-art experimental tools and molecular genetic methods adapted to C. parapsilosis, genome and transcriptome studies are now available that greatly contribute to our understanding of what makes this species a threat. In this review, we summarize 10 years of findings on C. parapsilosis pathogenesis, including the species' genetic properties, transcriptome studies, host responses, and molecular mechanisms of virulence. Antifungal susceptibility studies and clinician perspectives are discussed. We also present regional incidence reports in order to provide an updated worldwide epidemiology summary.

KW - antifungal

KW - Candida parapsilosis

KW - epidemiology

KW - experimental tools

KW - genome

KW - host response

KW - pathogenicity

KW - treatment

KW - virulence

UR - http://www.scopus.com/inward/record.url?scp=85062409041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062409041&partnerID=8YFLogxK

U2 - 10.1128/CMR.00111-18

DO - 10.1128/CMR.00111-18

M3 - Review article

C2 - 30814115

AN - SCOPUS:85062409041

VL - 32

JO - Clinical Microbiology Reviews

JF - Clinical Microbiology Reviews

SN - 0893-8512

IS - 2

ER -